Clinical Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
临床核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
基本信息
- 批准号:10589805
- 负责人:
- 金额:$ 30.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-10 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:3 year oldAdjuvantAfricaAgeAntibody ResponseAsthmaCanadaChildChild HealthClinicalClinical TrialsCommunicable DiseasesDataDevelopmentDiseaseFunctional disorderFutureGeographyGoalsGrowthHealthHypersensitivityImmuneImmune System DiseasesImmune responseImmune systemImmunologic MemoryImmunologicsImmunology procedureImpairmentIncidenceInfantInfectionInfection preventionInterventionIntestinesInvestigationLeadLifeLongitudinal cohort studyMeasuresModernizationMolecularMucous MembraneNasopharynxPapua New GuineaPhenotypePopulationPredispositionProspective cohortProteinsProteomicsRespiratory Tract InfectionsSamplingSecureShapesSystems BiologyTestingVaccinationVaccinesValidationVariantbiobankbiomarker developmentbiomarker discoveryclinical phenotypecohortdata exchangeearly childhoodimmune modulating agentsmetabolomicsmicrobiome researchmortalitymultiple omicspredictive markerpreventprospectiverecruitrespiratorytooltranscriptomicsvaccine responsevaccine-induced antibodies
项目摘要
Project Summary/Abstract – Clinical Core (CC)
The Clinical Core (CC) will provide and coordinate sharing of existing biorepository and new prospective clinical
samples collected from the systemic and mucosal (intestinal and nasopharyngeal) compartments from past and
ongoing early childhood cohorts to enable characterization of vaccine response-specific, respiratory infection-
specific, and asthma-specific OMIC signatures and endotypes. These discoveries will inform interventions that
may redirect unfavorable IDEAL endotypes associated with disease to those associated with health. Specifically,
the CC will:
1. Coordinate transfer of biorepository clinical samples from the four early life cohorts (EPIC-HIPC, VDAART,
Rochester Combined Cohort (RCC), and CHILD) that together will comprise our IDEAL Meta Cohort (IMC) to
Cores/Projects for OMIC and immune assays;
2. Measure vaccine induced antibody levels in VDART and CHILD cohorts; and
3. Recruit a well-defined prospective infant cohort to provide new samples for validation testing, confirm
predictive biomarkers, test mechanistic hypotheses, identify immunomodulatory agents (e.g., proteins,
metabolites, adjuvants or vaccines) overcoming impaired phenotype, and secure a new biorepository for future
investigations.
项目摘要/摘要-临床核心(CC)
临床核心(CC)将提供和协调现有生物信息库和新的预期临床的共享
从全身和粘膜(肠道和鼻咽)隔室收集的样本来自过去和
正在进行的儿童早期队列,以能够表征疫苗反应特异性的呼吸道感染-
特定的和哮喘特定的基因组特征和内型。这些发现将为干预措施提供信息
可能会将与疾病相关的不利理想内型重新定向到与健康相关的那些。具体来说,
消委会将:
1.协调从四个早期生命队列(EPIC-HIPC、VDAART、
Rochester联合队列(RCC)和CHILD),这将共同构成我们理想的Meta队列(IMC)以
基因组和免疫分析的核心/项目;
2.测量VDART和儿童队列中疫苗诱导的抗体水平;以及
3.招募一个定义明确的潜在婴儿队列,为验证测试提供新的样本,确认
预测生物标记物、检验机械假说、识别免疫调节剂(例如,蛋白质,
代谢物、佐剂或疫苗)克服受损的表型,并为未来确保新的生物储存库
调查。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL E PICHICHERO其他文献
MICHAEL E PICHICHERO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL E PICHICHERO', 18)}}的其他基金
Clinical Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
临床核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
- 批准号:
10435038 - 财政年份:2022
- 资助金额:
$ 30.47万 - 项目类别:
Immune biomarker discovery in children susceptible to recurrent otitis media
易患复发性中耳炎的儿童中免疫生物标志物的发现
- 批准号:
10452702 - 财政年份:2021
- 资助金额:
$ 30.47万 - 项目类别:
Immune biomarker discovery in children susceptible to recurrent otitis media
易患复发性中耳炎的儿童中免疫生物标志物的发现
- 批准号:
10286384 - 财政年份:2021
- 资助金额:
$ 30.47万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 30.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 30.47万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 30.47万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 30.47万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 30.47万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 30.47万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 30.47万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 30.47万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 30.47万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 30.47万 - 项目类别: